Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2019-03-07 Share Issue/Capital Cha…
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital) and explicitly references Article 223-16 of the AMF General Regulation. It provides a table detailing the total number of shares and voting rights as of February 28, 2019. This content directly corresponds to regulatory filings concerning changes in the total number of shares and voting rights, which is typically classified under Major Shareholding Notification (MRQ) or, more specifically for this type of recurring capital structure disclosure, sometimes falls under general regulatory announcements. However, given the specific nature of reporting total voting rights and shares, it aligns best with the intent of tracking significant capital structure changes or notifications related to ownership thresholds, which MRQ covers, or it could be a specific type of regulatory disclosure. Since the document is a formal, periodic disclosure of the total share capital and voting rights count, and not a director's dealing (DIRS) or a general share issue (SHA), it is a specific regulatory disclosure. In many classification schemes, this type of monthly capital structure update is often grouped with notifications related to share ownership changes or general regulatory updates. Given the options, and recognizing this is a mandatory disclosure about the total capital structure, it is closest to a Major Shareholding Notification (MRQ) if interpreted broadly as tracking capital base changes, or RNS if it's a standard, non-threshold-crossing monthly update. Since it is a formal, periodic report on the total capital structure, and not a specific transaction report, RNS (Regulatory Filings) is the most appropriate general category for mandatory, recurring disclosures that don't fit elsewhere, although MRQ deals with share ownership changes. Given the explicit focus on the *total* capital structure and voting rights count, which is a prerequisite for threshold monitoring, MRQ is a strong candidate, but RNS is the safest fallback for mandatory regulatory updates not explicitly defined. Let's re-evaluate the definitions. None perfectly match 'Total Voting Rights Disclosure'. MRQ is for *changes* in *significant share ownership*. This document reports the *total* capital base. Therefore, RNS (Regulatory Filings) is the most appropriate fallback for this mandatory, periodic regulatory disclosure that doesn't fit the specific transaction/event codes.
2019-03-07 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Capital/Financing Update Classification · 99% confidence The document is a press release dated March 4, 2019, announcing that Nanobiotix received €14 million from the European Investment Bank (EIB) as the second tranche of a financing agreement. The core subject is the receipt of funds related to achieving specific clinical milestones and strengthening the balance sheet. This clearly falls under the category of updates regarding company fundraising, financing activities, or capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2019-03-04 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Capital/Financing Update Classification · 99% confidence The document is a press release dated March 4, 2019, announcing that Nanobiotix received a €14 million payment from the European Investment Bank (EIB) as the second tranche of a loan. The text details the achievement of performance criteria necessary to unlock this financing tranche and discusses the impact on the company's balance sheet and clinical development plans for NBTXR3. This type of announcement, focusing on fundraising, financing activities, and capital structure updates (specifically drawing down a loan), aligns directly with the definition of 'Capital/Financing Update'. It is not an earnings release (ER), an interim report (IR), or a formal regulatory filing like a 10-K. Therefore, the appropriate code is CAP.
2019-03-04 French
Communicated under the obligation to provide permanent information / Information on annual revenues
Earnings Release Classification · 98% confidence The document is a press release dated February 28, 2019, announcing the 'unaudited revenues for Q4 and the unaudited annual revenues for the year ended December 31, 2018.' It presents key financial figures (revenues) for the fourth quarter and the full year, along with a future financial agenda. This content structure—announcing period-specific financial results (Q4 and Annual) in a press release format—is characteristic of an Earnings Release (ER). It is not the comprehensive Annual Report (10-K), nor is it a full transcript (CT) or a detailed management discussion (MDA). It is the initial announcement of the period's results. Q4 2018
2019-02-28 English
Communiqués au titre de l'obligation d'information permanente / Information sur chiffre d’affaires annuel
Earnings Release Classification · 98% confidence The document is titled "Chiffre d'affaires du quatrième trimestre et de l'exercice 2018" (Revenue for the fourth quarter and the 2018 fiscal year) and presents detailed, non-audited financial figures for the full year 2018 and Q4 2018, including comparative data from 2017. It also includes a financial calendar mentioning the announcement of 'résultats annuels 2018' (annual results 2018) on March 15, 2019. Since this document explicitly reports the full year's revenue figures and operational highlights, it functions as an Earnings Release (ER) or a component thereof, rather than the comprehensive Annual Report (10-K) or the subsequent comprehensive Interim/Quarterly Report (IR). Given the focus on period-end financial results announcement, 'ER' (Earnings Release) is the most appropriate classification, as it precedes the full annual filing. Q4 2018
2019-02-28 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital) and explicitly references Article 223-16 of the AMF (Autorité des Marchés Financiers) General Regulation. It provides a table detailing the total number of shares and voting rights as of January 31, 2019. This type of regular disclosure concerning the total share capital and voting rights is a specific regulatory requirement in France, often related to changes in major shareholdings or capital structure transparency. While it touches upon capital structure, it is a specific monthly disclosure of voting rights rather than a general capital change announcement (SHA) or a major shareholding notification (MRQ) which usually reports an entity crossing a threshold. Given the options, this specific monthly disclosure of voting rights and total shares most closely aligns with the intent of tracking ownership changes and capital structure transparency, but it doesn't perfectly match the defined codes. However, it is a mandatory regulatory filing. Since it is a specific, recurring regulatory disclosure that doesn't fit perfectly into the defined categories like DIV, SHA, or MRQ, the most appropriate fallback category for a specific, non-standard regulatory report is RNS (Regulatory Filings). It is not an ER, IR, or 10-K, nor is it a management/board change or a dividend notice. It is a formal regulatory update.
2019-02-07 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.